Dr. Nada M. Elbuluk, MD

Dr. Elbuluk practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Elbuluk's NPI, 1013146307, was assigned on July 7, 2009. Dr. Elbuluk graduated from University Of Michigan Medical School in 2009. Dr. Elbuluk holds California license A154630.

Dr. Elbuluk's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Elbuluk's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Elbuluk to 1 more group practice or clinic and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Elbuluk practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Elbuluk's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Elbuluk is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Elbuluk's licenses on file in 4 states: California, New York, Pennsylvania and Michigan.

Dmand AI lists acne, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, hives, itchy rashes, scalp rash and skin cyst among the conditions Dr. Elbuluk treats.

CMS data shows 145 Medicare services from Dr. Elbuluk across 5 procedure codes in 2024, for 54 Medicare patients. Medicare paid $11,579 for them. Every service was in an office.

CMS counts 54 Medicare patients who saw Dr. Elbuluk in 2024. The largest group is 65 to 74, with 29 patients. 70% of them have high blood pressure, and 69% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.03, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Elbuluk's median patient age at 46, with 67% women.

In 2024, Dr. Elbuluk wrote 175 Medicare Part D claims for 44 patients. 90% of them were for generic drugs. CMS names the drug for 106 of them, across 6 drugs with 11 or more claims each, at $26,146 in total drug cost. In 2023, CMS named 89 claims across 5 drugs.

Dr. Elbuluk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Elbuluk as offering telehealth. CMS counts 28 procedures of removal of skin lesions by Dr. Elbuluk, more than 68% of the clinicians it reports for that procedure.

Dmand AI links 27 papers to Dr. Elbuluk, published from 2010 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Dermatology, Black or African American and Ethnic and Racial Minorities. Dr. Elbuluk has published most often in J Drugs Dermatol. Dr. Elbuluk's most frequent co-authors are Pearl E. Grimes, MD, Teo Soleymani, MD and Andrew F. Alexis, MD.

Dmand AI links Dr. Elbuluk to 1 clinical trial. Conditions studied include Vitiligo and Hypopigmentation.

CMS Open Payments shows 157 general payments to Dr. Elbuluk from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 86% of the total. Incyte Corporation paid the most, $81,075. It also lists 5 research payments totaling $8,610 from 2024 to 2025.

Dmand AI lists 1 award for Dr. Elbuluk, most recently CMS Stage 1 EHR in 2013.

Dr. Elbuluk graduated from University Of Michigan Medical School in 2009. Dr. Elbuluk is a member of AAD.

Dr. Elbuluk is in network with 8 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.